Beschreibung
The service is requested as part of the Companys efforts to develop therapeutic options to treat or prevent COVID-19 infections and related complications (target indications). The project has the ultimate purpose to provide equitable access to two of the Companys COVID-19 treatments under emergency conditions and to guide their most appropriate use. More specifically, it will inform the development of evidence generation strategies and (abbreviated) value dossiers for two COVID-19 treatments, in light of public and government scrutiny, potential supply shortages requiring benefit stratification, non-standard Health Technology Assessment (HTA) pathways, and frequently sub-optimal pandemic response plans on national/regional and local levels.
- Independent interpretation and consolidation of HTA reports, market research, existing internal analyses and publically available data on the evidence requirements of payers, HTA agencies and pandemic response teams to develop evidence generation strategies and (abbreviated) value dossiers for two COVID-19 treatments in the target indications
- Evaluation and assessment of payer insights on evidence needs in relevant treatment and (emergency) care pathways for the two COVID-19 treatments in their target indications based on extensive external expertise in Health Economics & Outcomes Research (HEOR)
- Conduct and roll-out of literature reviews on the health economic value of key competitor products in our target indications
-
Development and delivery of key elements of the value story and (abbreviated) dossier to demonstrate and communicate the value of the two compounds to payers, HTA agencies and pandemic response teams on national, regional and local levels and to provide results for integrating them into pandemic response plans
